Microgestin Fe 1.5/30 Kit
Product Images NDC 82804-096

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Microgestin Fe 1.5/30 (NDC 82804-096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 01)

Chemical structure diagrams of the active ingredients Norethindrone Acetate and Ethinyl Estradiol from the Microgestin Fe 1.5/30 kit by Proficient Rx LP. The image shows the molecular formulas represented in skeletal form for both compounds side by side.*

FDA Label Image

2 (Image 02)

A data table titled 'Lowest Expected and Typical Failure Rates During the First Year of Continuous Use of a Method' showing percentages of women experiencing unintended pregnancy with various contraceptive methods. Methods listed include no contraception, oral contraceptives (combined and progestin only), diaphragms, spermicides, vaginal sponge, implants, injections, IUDs, condoms, cervical caps, periodic abstinence, withdrawal, and sterilization. Both lowest expected and typical failure rates are presented where available.*

FDA Label Image

3 (Image 03)

A warning text panel highlighting the increased risk of serious cardiovascular side effects from oral contraceptive use associated with cigarette smoking. Risk is noted to increase with age and heavy smoking (15 or more cigarettes per day), especially in women over 35 years. It advises women using oral contraceptives to strongly avoid smoking.*

FDA Label Image

4 (Image 04)

A bar chart showing circulatory disease mortality rates per 100,000 women by age groups and oral contraceptive use status. The chart compares mortality rates between ever-users and controls, separated into non-smokers and smokers, across four age groups: 15-24, 25-34, 35-44, and 45+. Mortality rates increase with age, especially high among smokers aged 45 and older who used oral contraceptives.*

FDA Label Image

5 (Image 05)

A data table titled 'Annual Number of Birth-Related or Method-Related Deaths Associated with Control of Fertility per 100,000 Nonsterile Women by Fertility Control Method According to Age.' It presents death rates by age groups and fertility control methods, including no fertility control, oral contraceptives (smoker and non-smoker), IUD, condom, diaphragm/spermicide, and periodic abstinence. Annotations note which deaths are birth-related or method-related.*

FDA Label Image

6 (Image 06)

A warning text panel stating that cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. The risk is higher with age and heavy smoking (15 or more cigarettes per day), particularly in women over 35 years, and advises women who use oral contraceptives not to smoke.*

FDA Label Image

7 (Image 07)

An instructional diagram showing the Microgestin Fe 1.5/30 pill pack with 21 yellow active pills for weeks 1 to 3, followed by brown inactive pills for week 4. The image depicts a hand placing a day label sticker on the pill pack and directions to take the pills from left to right each week, including a note for day 1 starters.*

FDA Label Image

8 (Image 08)

A text panel warning about increased risk of serious cardiovascular side effects from oral contraceptive use associated with cigarette smoking. It highlights that the risk increases with age and heavy smoking (15 or more cigarettes per day), especially in women over 35 years, and strongly advises women using oral contraceptives not to smoke.*

FDA Label Image

9 (Image 09)

A boxed warning panel conveying that cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use, with a heightened risk for women over 35 years of age and those who smoke 15 or more cigarettes per day. It advises women using oral contraceptives not to smoke.*

FDA Label Image

10 (Image 10)

A data table showing annual number of birth-related or method-related deaths associated with control of fertility per 100,000 nonsterile women by fertility control method according to age groups ranging from 15-19 to 40-44. Methods include no fertility control, oral contraceptives (non-smoker and smoker), IUD, condom, diaphragm/spermicide, and periodic abstinence, with death counts provided for each age and method category.*

FDA Label Image

11 (Image 11)

An instructional diagram illustrating the pill-taking schedule for the Microgestin Fe 1.5/30 oral contraceptive kit. It shows a hand holding a pill blister card with 21 yellow active pills for weeks 1, 2, and 3, and 7 brown inactive pills for week 4. The diagram includes labeled days of the week and directional arrows indicating the left-to-right weekly pill sequence.*

FDA Label Image

12 (Image 12)

FDA Label Image

82804-096-28 (Image 13)

The label for Microgestin FE 1.5/30mcg tablets, a kit containing 28 tablets. It specifies 21 yellow tablets each with 1.5 mg norethindrone acetate and 0.03 mg ethinyl estradiol, and 7 brown tablets each with 75 mg ferrous fumarate. Distributed by Mayne Pharma, manufactured in China, and relabeled by Proficient Rx LP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.